STAT
JUNE 17, 2024
Patent and Trademark Office has proposed a new rule designed to stem the use of so-called patent thickets , which are wielded by pharmaceutical companies to delay the arrival of lower-cost generic medicines in the marketplace. In a bid to prevent the patent system from being abused, the U.S.
STAT
DECEMBER 4, 2024
Patent & Trademark Office has withdrawn a controversial proposal that was designed to prevent pharmaceutical companies from abusing the patent system.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
SEPTEMBER 14, 2023
The Federal Trade Commission warned pharmaceutical companies they could face legal action if they improperly list patents for brand-name medicines in a Food and Drug Administration registry, the latest effort by the federal government to scrutinize patent moves by drugmakers.
STAT
MARCH 21, 2023
government to remove the key negotiator working on a free trade agreement with the Indian government because of his previous ties to a major pharmaceutical company. More than 200 civil society and patient advocacy groups are urging the U.K. Now, the groups are upset that the involvement of Harjinder Kang, the U.K.
European Pharmaceutical Review
MARCH 14, 2023
The CJEU stressed that identical medicinal products are not those that are only therapeutically equivalent (as generics are to reference products), but they should be identical in all respects. He has been advising pharmaceutical companies and healthcare providers for a number of years.
Pharmaceutical Technology
DECEMBER 19, 2022
This economic change impacts employment, income, industrial production, and more, and the pharmaceutical industry will not be exempt. While larger, more established pharmaceutical companies may have the infrastructure and financial cushion to fall back on, SMEs need to tread carefully through these economic challenges.
European Pharmaceutical Review
FEBRUARY 2, 2023
This left pharmaceutical companies in Europe with no European API supply source, and only a few suppliers in Asia. A recent example was the sudden shortage of the API tamoxifen, used in a key breast cancer therapy, as the only European API manufacturer halted production because it had become uneconomical.
Expert insights. Personalized for you.
128 
Let's personalize your content